Related Experiment Video
Updated: Sep 23, 2025
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
Hualin Chen1, Yipin Luo2, Muwen Lin1
1Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Background:
The aim of the present study was to summarize the clinical and pathological characteristics of 11 non-small cell lung cancer (NSCLC) patients with mesenchymal-epithelial transition factor exon 14 skipping (METex14).
Methods:
From 2018 to 2021, medical records of 763 NSCLC patients were reviewed and 11 patients carrying METex14 were identified from the Affiliated Hospital of Guangdong Medical University. Their clinical data were subsequently examined for pathological and related clinical information including symptom and diagnosis, imaging and follow-up.
Results:
The METex14 cohort includes 9 males and 2 females and the age range was 69-85 years, with a median age of 77 years. Of the patients one is diagnosed with stage IVB lung adenosquamous carcinoma, 7 with lung adenocarcinoma (1 with stage IIIA and 6 with stage IV), and 3 with stage IV lung sarcomatoid carcinoma. 3 reached stable disease until the end of follow-up and 4 died within a year due to multiple metastases. In 4 cases, the patients received selective MET inhibitor treatment all lived longer than 7 months. There were 4 heterozygous point mutations and 1 deletion of the MET gene in this cohort, as follows: c.G3028T (p.D1010Y); c.G3028A (p.D1010N); c.G3005C (p.V1002A); c.3022C>G and MET c.3021_3028+20del (E14).
Conclusions:
According to the data that we collected, the incidence of NSCLC carrying METex14 is low and male outnumber female in our sample pool. Selective target therapy had better prognosis than multitargeted tyrosine kinase inhibitor (TKI) such as crizotinib or standard therapy.
Insights
This study reviewed 11 non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping (METex14). Selective MET inhibitor therapy showed a better prognosis compared to other treatments for this rare NSCLC subtype.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Non-small cell lung cancer (NSCLC) is a major cause of cancer-related mortality.
- Mesenchymal-epithelial transition factor (MET) exon 14 skipping (METex14) is a rare but actionable driver mutation in NSCLC.
- Understanding the clinical and pathological features of METex14-altered NSCLC is crucial for targeted therapy selection.
Purpose of the Study:
- To summarize the clinical and pathological characteristics of NSCLC patients with METex14.
- To evaluate the treatment outcomes and prognostic factors in this specific NSCLC cohort.
- To identify potential therapeutic strategies for METex14-positive NSCLC.
Main Methods:
- Retrospective review of medical records from 763 NSCLC patients diagnosed between 2018 and 2021.
- Identification of 11 patients with METex14 alterations using genomic analysis.
- Detailed examination of clinical data, including symptoms, diagnosis, imaging, treatment, and follow-up.
Main Results:
- The METex14 cohort comprised 9 males and 2 females, with a median age of 77 years.
- Histological subtypes included lung adenocarcinoma, adenosquamous carcinoma, and sarcomatoid carcinoma, predominantly in advanced stages (Stage IV).
- Selective MET inhibitor therapy demonstrated improved survival outcomes compared to standard therapies or multi-targeted tyrosine kinase inhibitors (TKIs).
Conclusions:
- The incidence of NSCLC with METex14 is low, with a male predominance in the studied population.
- Selective MET inhibitors represent a promising therapeutic approach for METex14-altered NSCLC, offering better prognosis.
- Further research is warranted to explore the full spectrum of METex14 alterations and optimize treatment strategies.
